skip to main content

H.R. 2276 (112th): To require the Director of the United States Patent and Trademark Office to conduct a study on effective ways to provide confirming genetic diagnostic test activity where gene patents and exclusive licensing exist, and for other purposes.

Sponsor and status

Debbie Wasserman Schultz

Sponsor. Representative for Florida's 20th congressional district. Democrat.

Read Text »
Last Updated: Jun 22, 2011
Length: 3 pages
Introduced:

Jun 22, 2011
112th Congress, 2011–2013

Status:
Introduced

Provisions of this bill were incorporated into other bills which were enacted.

This bill was incorporated into:

H.R. 1249: Leahy-Smith America Invents Act
Enacted — Signed by the President on Sep 16, 2011. (compare text)

History

Jun 22, 2011
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

H.R. 2276 (112th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 112th Congress, which met from Jan 5, 2011 to Jan 3, 2013. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“H.R. 2276 — 112th Congress: To require the Director of the United States Patent and Trademark Office to conduct a ...” www.GovTrack.us. 2011. December 16, 2018 <https://www.govtrack.us/congress/bills/112/hr2276>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.